Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
- Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.
- Publication status:
- Publisher copy:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publication date:
- Source identifiers:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright date:
If you are the owner of this record, you can report an update to it here: Report update to this record